Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

Panel Discussion: TELLOMAK Clinical Trial

May 2021: A panel discussion about the TELLOMAK clinical trial evaluating lacutamab in patients with advanced T-cell lymphomas, including Sézary syndrome and mycosis fungoides. Dr. Youn Kim and Dr. Joyson Karakunnel join Susan Thornton to discuss the clinical perspective of the study, where the study is today, preliminary data to share from the trial and more.

Joyson Karakunnel, MD, MSc, FACP, Innate Pharma 
Youn Kim, MD, Stanford Health Care
Susan Thornton, CEO, Cutaneous Lymphoma Foundation

Panel Discussion: Elorac Clinical Trial for Naloxone

December 2020: Elorac is currently engaged in a clinical trial for topical naloxone, which targets itch in mycosis fungoides and Sezary Syndrome. Members of the Elorac team joined Susan Thornton for a discussion about this promising treatment for managing itch.

Heidi Fezatte, Director, Clinical Compliance, Elorac, Inc.
Scott Phillips, MD, Senior Vice President, Scientific Affairs, Elorac, Inc.
Susan Thornton, CEO, Cutaneous Lymphoma Foundation

Panel Discussion: FLASH Clinical Trial Update

June 2020: The FLASH (Fluorescent Light Activated Synthetic Hypericin) Study, a phase 3 trial by Soligenix, is a potential new treatment for early stage cutaneous lymphoma using visible fluorescent light. Susan Thornton, CEO, was joined by Drs. Ellen Kim, Chris Pullion and Richard Straube to discuss this exciting technology.

Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine
Richard Straub, MD, Chief Medical Officer, Soligenix, Inc.
Chris Pullion, DO, Medical Director, Soligenix Inc.

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR®

April 2020 - Helsinn Therapeutics (U.S.), Inc., the US subsidiary of the Swiss pharmaceutical group focused on building quality cancer care products, today announces a change to the financial assistance program for VALCHLOR® (mechlorethamine) gel 0.016% to ensure that commercially insured patients have access to treatment during the COVID-19 crisis.

FLASH Clinical Trial- Update

Positive results were announced earlier this year for the FLASH Study, a phase 3 clinical trial in CTCL, by Soligenix. SGX301 is a novel first-in-class photodynamic therapy utilizing safe visible light for activation.

American Society of Hematology Announces 2020 Scholar Award Recipients

December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 

Clinical Trials...Developing Innovative Drug Candidates to Improve the Lives Of Cancer Patients

Two clinical assets of Trillium Therapeutics Inc., TTI-621 and TTI-622, are designed to activate the patient’s innate and adaptive immune response. TTI-621 is an investigational agent being developed by Trillium for the treatment of cutaneous T-cell lymphoma and other cancer types.

FDA Approves Mogamulizumab for CTCL

The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.

Industry Spotlight: Adaptive Biotechnologies

Susan Thornton, CEO, interviewed Adaptive Biotechnologies, creators of an innovative diagnostic tool that can be used in cutaneous lymphoma.

Research in Cutaneous Lymphoma: A Broad View

Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.

FLASH Study: Clinical Trial Update

Dr. Ellen Kim shares information about the role of clinical trials and specifically the FLASH [Fluorescent Light Activated Synthetic Hypericin] Study.

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides

Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma

For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.


Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.